ArticleOncology letters2026

Adverse events induced by the subcutaneous HER2-targeted antibody-drug conjugate JSKN033 in a male patient with breast cancer: A case report.

Rui Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.